Patents by Inventor Jean-Claude Tardif

Jean-Claude Tardif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210290623
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 23, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Publication number: 20210236442
    Abstract: The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 5, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Fouzia LAGHRISSI-THODE
  • Publication number: 20210145773
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 20, 2021
    Inventor: Jean-Claude TARDIF
  • Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20200239960
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20200222406
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 10584385
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20190284527
    Abstract: The present invention provides a co-culture system and method for assessing cellular cholesterol (Choi) efflux and uptake in vitro. The co-culture system mimics in vivo Choi efflux and uptake in the context of mammalian physiology. The methods and systems provided can be used in some embodiments to evaluate the effect of a pharmacological agent on cellular Choi efflux and uptake or for diagnostic purposes.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 19, 2019
    Inventors: David RHAINDS, Éric RHÉAUME, David BUSSEUIL, Jean-Claude TARDIF
  • Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20190070178
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 7, 2019
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Publication number: 20180155784
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20170233812
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 25, 2017
    Publication date: August 17, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20160244826
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 25, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20160230231
    Abstract: The invention relates to genetic variants useful for evaluating creatine kinase levels in a subject and determining an Nupper limit of normal (ULN) CK level for a subject. ULN CK level is used in determining the pathological significance of measures of blood or plasma CK obtained from the subject. The methods and compositions of the invention are useful for providing a genetic-C ally determined or individualized ULN CK level, for diagnosing statin-induced myopathy and for providing statin therapy.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 11, 2016
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20150374675
    Abstract: The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Inventors: Jean-Claude TARDIF, David BUSSEUIL, Eric RHÉAUME
  • Publication number: 20140309426
    Abstract: The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 16, 2014
    Inventors: Jean-Claude TARDIF, David Busseuil, Eric Rhéaume
  • Publication number: 20130197226
    Abstract: The present invention features pharmaceutical compositions and methods of using the pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.
    Type: Application
    Filed: July 19, 2011
    Publication date: August 1, 2013
    Inventors: Jean-Claude Tardif, David Busseuil, Éric Rhéaume
  • Patent number: 8163699
    Abstract: A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: April 24, 2012
    Assignee: Montreal Heart Institute
    Inventor: Jean-Claude Tardif